Skip to main content

Table 2 Change from baseline in patient-reported outcome measures with and without MO

From: The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study

 

CM With MO

CM Without MO

 

Fremanezumab

 

Fremanezumab

 
 

Quarterly

(n = 201)

Monthly

(n = 198)

Placebo

(n = 188)

Quarterly

(n = 174)

Monthly

(n = 177)

Placebo

(n = 188)

HIT-6

 LSM (SE)

−6.0 (0.7)

−6.9 (0.6)

−4.5 (0.7)

−7.0 (0.7)

− 6.8 (0.64)

−4.5 (0.6)

  LSMD (SE)

− 1.5 (0.7)

−2.4 (0.7)

 

−2.4 (0.7)

− 2.3 (0.7)

 

  P value

0.0356

0.0009

 

0.0006

0.0012

 

MSQoL, RFR

 LSM (SE)

19.6 (1.8)

21.4 (1.8)

14.7 (1.9)

21.9 (2.0)

21.6 (2.0)

14.5 (1.9)

  LSMD (SE)

4.9 (2.0)

6.7 (2.0)

 

7.4 (2.1)

7.1 (2.1)

 

  P value

0.0142

0.0008

 

0.0005

0.0008

 

MSQoL, RFP

 LSM (SE)

17.5 (1.7)

18.4 (1.6)

14.2 (1.7)

16.4 (1.7)

14.2 (1.7)

10.2 (1.7)

  LSMD (SE)

3.2 (1.8)

4.2 (1.8)

 

6.2 (1.8)

3.9 (1.8)

 

  P value

0.0696

0.0200

 

0.0007

0.0290

 

MSQoL, EF

 LSM (SE)

20.2 (2.0)

22.0 (1.9)

17.3 (2.0)

22.4 (2.1)

19.7 (2.1)

16.7 (2.1)

  LSMD (SE)

2.9 (2.2)

4.7 (2.2)

 

5.7 (2.3)

3.0 (2.3)

 

  P value

0.1833

0.0305

 

0.0118

0.1873

 

PHQ-9

 LSM (SE)

−2.8 (0.4)

−2.3 (0.4)

−2.4 (0.4)

−2.6 (0.4)

−2.3 (0.4)

−1.6 (0.4)

  LSMD (SE)

−0.5 (0.4)

0.0 (0.4)

 

−1.0 (0.4)

−0.7 (0.4)

 

  P value

0.2679

0.9678

 

0.0155

0.0922

 
  1. CM Chronic migraine, EF Emotional function, HIT-6 Six-item Headache Impact Test, LSM Least-squares mean, LSMD Least-squares mean difference, MO Medication overuse, MSQoL Migraine-Specific Quality of Life, RFP Role function–preventive, RFR Role function–restrictive, PHQ-9 Patient Health Questionnaire-9, SE Standard error
  2. LSMD was determined in comparison to placebo